Not losing weight on Wegovy 0.25mg — is that normal?

Why does 0.25mg exist if it doesn't cause weight loss?

A question our prescribers hear most weeks, honestly. Patients start Wegovy, watch four weeks pass, and wonder whether something has gone wrong. Nothing has.

The 0.25mg dose was designed with one job: helping your body adapt to semaglutide without overwhelming it with gastrointestinal side effects. GLP-1 medicines slow gastric emptying and alter gut signalling, and starting at a full therapeutic dose would make nausea and vomiting far more likely for most people. The starter pen is essentially a settling-in period, not a weight-loss phase.

This is built into the licensed schedule. The STEP 1 trial that established Wegovy's effectiveness enrolled participants who reached 2.4mg maintenance, the STEP 1 results published in the New England Journal of Medicine reported an average of around 15% body weight reduction over 68 weeks at that dose. The 0.25mg phase is simply not the part of the schedule those results came from. If you're at week four and the number hasn't changed, you're where the evidence says you should be.

It can feel counterintuitive when you're motivated and ready to see results. But rushing past the starter dose doesn't accelerate the outcome, it usually just increases the chance of side effects that make treatment harder to sustain.

What actually happens as the dose goes up?

As the prescribing schedule moves from 0.25mg through 0.5mg, 1mg and 1.7mg toward 2.4mg, semaglutide's effect on appetite and satiety increases. People typically report feeling full more quickly at meals, thinking about food less between meals, and finding it easier to stop eating before they're uncomfortable.

These appetite changes are what drives weight loss, and they tend to become more noticeable from around the 0.5mg and 1mg stages onward. You can read more about how results tend to evolve at each step on our page covering what to expect when weight loss stalls at 0.5mg.

The MHRA-approved Wegovy schedule also now includes a 7.2mg maximum dose for eligible patients, approved in early 2026, where trial data suggested average losses of around 20.7% over 72 weeks. That context matters mainly to illustrate how much further the journey can go, the 0.25mg phase is genuinely just the start.

For most patients, steady month-by-month titration is the framework their prescriber uses. Jumping doses is not recommended and could increase side-effect burden. Patience here is clinical advice, not a platitude.

Is there anything I should do differently right now?

While your dose is low and weight loss hasn't begun yet, the habits you build still matter. Semaglutide works alongside a reduced-calorie diet and increased physical activity, that's part of the licensed indication, not optional small print. The medicine reduces appetite; the lifestyle context determines how well you use that change.

Protein intake is worth paying attention to from the start. As appetite falls at higher doses, some people find they eat so little that muscle mass suffers. Getting enough protein while you can still eat relatively normally sets a useful pattern. The NHS Live Well healthy weight guidance has practical starting points, though your own plan should be discussed with your prescriber or a dietitian.

Hydration matters too, particularly because GLP-1 medicines can occasionally cause enough nausea or vomiting to lead to dehydration. Even at 0.25mg, keeping fluid intake up is sensible.

If you have questions about whether the schedule is right for your situation, or if side effects are bothering you more than expected, our team is available seven days a week to help. Dose concerns should go to your prescriber, not forums, not social media.

When should I actually start to worry?

The short version: not yet, almost certainly. But there are situations worth flagging to a prescriber sooner rather than later.

If you reach 2.4mg, the maintenance dose, and after six months of treatment have lost less than 5% of your starting body weight, clinical guidance suggests reviewing whether continuing is right for you, that threshold comes from NICE's recommendation process and is built into how prescribers evaluate ongoing treatment. That conversation happens months from now, not in week four.

If you're already at higher doses and feeling stuck, the pages covering weight loss stalling at 1mg, what to do when progress slows at 1.7mg, and plateaus at 2.4mg go into more specific detail on what to consider.

Right now, at 0.25mg, the most evidence-backed thing you can do is continue the schedule, take care of the lifestyle factors you can control, and trust that the dose that drives results is coming. A full overview of the Wegovy dose schedule and what each stage involves is worth reading if you'd like to see the whole pathway laid out clearly.

If you're thinking about what treatment options are available to you, or whether Wegovy is the right fit compared to other licensed medicines, starting a free consultation with our prescribers is the straightforward next step.